If it is approved, SeattleGenetics will market brentuximab vedotin usin a sales force of only sixty or so sales representatives in the U.S. and Canada.
Developed using technology from partner SeattleGenetics, the drug is a monoclonal antibody containing a toxic chemotherapy that attacks cancer cells if they express glycoprotein NMB, or GPNMB.